Baird raised the firm’s price target on Cogent Biosciences (COGT) to $34 from $14 and keeps a Neutral rating on the shares. The firm updated its model following positive Phase 3 PEAK data for Bezu/Sunitnib combo in 2L GIST.
Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on COGT:
- Cogent announces $200M convertible senior notes, $200M common stock offerings
- Cogent Biosciences: Promising Outlook with Breakthrough GIST Treatment and Strategic Growth Plans
- Cogent Biosciences’ Bezuclastinib Shows Promising Phase 3 Results, Boosting Buy Rating and Price Target
- Cogent Biosciences price target raised to $45 from $30 at Jefferies
- Cogent Biosciences price target raised to $50 from $18 at Leerink